Microcirculatory changes in patients with chronic obstructive pulmonary disease and arterial hypertension
https://doi.org/10.21886/2712-8156-2022-3-1-34-41
Abstract
Objective: to study the dynamics of microcirculation indices in patients with arterial hypertension, chronic obstructive pulmonary disease, and in their combination. Material and methods: the study included 226 people, of which 66 people were patients with chronic obstructive pulmonary disease, 54 patients with arterial hypertension, 74 people with a combination of chronic obstructive pulmonary disease and arterial hypertension, 32 relatively healthy volunteers. To assess the circulatory bed, we used a computerized ultrasonic Doppler instrument Minimax-Doppler-K, LLC JV «Minimax». Results: in patients with COPD and AH, microcirculation maladjustment is observed, manifested by a paradoxical reaction to stimuli in the form of an indirect occlusive effect. When studying the correlations between the indicators of the microvasculature and clinical and instrumental data, it was found that there is a relationship between the linear velocities of the microvasculature and the age, the smoking index, systolic blood pressure, pulse blood pressure. A correlation relationship was established between the FEV1 and the maximum linear systolic velocity along the maximum velocity curve in patients with COPD and COPD and AH. Conclusion: COPD and hypertension are comorbid conditions that lead to more pronounced microcirculatory changes, which can have a mutual effect on the course of these diseases.
About the Authors
S. E. Glova
Rostov State Medical University
Russian Federation
Russian Federation
Svetlana E. Glova - Cand. Sci. (Med.), Associate Professor, Chair of Therapy, The Rostov State Medical University.
Rostov-on-Don.
L. A. Khaisheva
Rostov State Medical University
Russian Federation
Russian Federation
Larisa A. Khaisheva - Dr. Sci. (Med.), P rofessor, Chair of Therapy, The Rostov State Medical University.
Rostov-on-Don.
I. V. Razumovsky
Rostov State Medical University
Russian Federation
Russian Federation
Igor V. Razumovsy - MD, postgraduate, Chair of Therapy, The Rostov State Medical University.
Rostov-on-Don.
S. V. Shlyk
Rostov State Medical University
Russian Federation
Russian Federation
Sergey V. Shlyk - Dr. Sci. (Med.), Professor, Chair of Therapy, Rector, The Rostov State Medical University.
Rostov-on-Don.
References
1. Greulich T, Weist BJD, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population. Respir Med. 2017;132:132-138. DOI: 10.1016/j.rmed.2017.10.007.
2. Finks SW, Rumbak MJ, Self TH. Treating Hypertension in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2020;382(4):353-363. DOI: 10.1056/NEJMra1805377.
3. Australian Institute of Health and Welfare. Chronic obstructive pulmonary disease (COPD), associated comorbidities and risk factors. Canberra: Australian Institute of Health and Welfare; 2020.
4. Beaty TH, Newill CA, Cohen BH, Tockman MS, Bryant SH, Spurgeon HA. Effects of pulmonary function on mortality. J Chronic Dis. 1985;38(8):703-10. DOI: 10.1016/0021-9681(85)90024-4.
5. Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10(12):2794-800. DOI: 10.1183/09031936.97.10122794.
6. Задионченко В.С., Волкова Н.В., Копалова С.М. Системная и легочная гипертония при хронических неспецифических заболеваниях легких. Русский медицинский журнал. 1996;4(12):28-37.
7. Задионченко В.С., Адашева Т.В., Шилова Е.В. и др. Клиникофункциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. Русский медицинский журнал. 2003;11(9):535-8.
8. Кубышкин В.Ф., Солдатченко С.С., Коновалов В.И. Особенности течения хронических обструктивных заболеваний легких в сочетании с системной артериальной гипертензией. Терапевтический архив. 1985;57(2):114-6.
9. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest. 2003;123(1):222-43. DOI: 10.1378/chest.123.1.222.
10. Chazova I.E., Lazareva N.V., Oshchepkova E.V. Arterial hypertension and chronic obstructive pulmonary disease: clinical characteristics and treatment efficasy (according to the national register of arterial hypertension). Therapeutic Archive. 2019;91(3):4-10. DOI: 10.26442/00403660.2019.03.000110.
11. Aliverti A, Macklem PT. How and why exercise is impaired in COPD. Respiration. 2001;68(3):229-39. DOI: 10.1159/000050502.
12. Figueira Goncalves JM, Dorta Sanchez R, Rodri Guez Perez MDC, Vina Manrique P, D^az Perez D, Guzman Saenz C, et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). Clin Investig Arterioscler. 2017;29(4):149-156. (In English, Spanish). DOI: 10.1016/j.arteri.2017.01.003.
13. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618-24. DOI: 10.1378/chest.128.5.3618.
14. Magalhaes GS, Rodrigues-Machado MG, Motta-Santos D, Silva AR, Caliari MV, Prata LO, et al. Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol. 2015;172(9):2330-42. DOI: 10.1111/bph.13057.
15. Vasileiadis IE, Goudis CA, Giannakopoulou PT, Liu T. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease? COPD. 2018;15(2):148-156. DOI: 10.1080/15412555.2018.1432034.
16. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009;18(114):222-32. DOI: 10.1183/09059180.00005309.
17. Адашева Т.В., Саморукова Е.И., Долбин С.С., Ли В.В., Зади-онченко В.С., Высоцкая Н.В. Хроническая обструктивная болезнь легких и артериальная гипертензия: существуют ли особенности ведения пациентов? РМЖ. 2020;3:32-38. eLIBRARY ID: 42666140.
18. Овчаренко С.И. Сердечно-сосудистая патология у больных хронической обструктивной болезнью легких: как мы лечим? РМЖ. 2018;10(I):36-39. eLIBRARY ID: 36152068.
19. Овчаренко С. И., Нерсесян З. Н., Морозова Т. Е. Хроническая обструктивная болезнь легких в сочетании с артериальной гипертонией: оценка системного воспаления и эндотелиальной дисфункции. Пульмонология. 2015;(5):561-567. eLIBRARY ID: 25140026.
20. Клинические рекомендации. Хроническая обструктивная болезнь легких МКБ-10: J44 Год утверждения (частота пересмотра): 2018 (пересмотр каждые 3 года). ID: КР603 Российское респираторное общество.
21. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786.
Review
For citations:
Glova S.E., Khaisheva L.A., Razumovsky I.V., Shlyk S.V. Microcirculatory changes in patients with chronic obstructive pulmonary disease and arterial hypertension. South Russian Journal of Therapeutic Practice. 2022;3(1):34-41. (In Russ.) https://doi.org/10.21886/2712-8156-2022-3-1-34-41
Views:
575
Email this article 